Table 1 Clinicopathological data
Clinicopathologic Diagnosis | Histologic Diagnosis | Gender | Age (years) | Follow-up (months) | Relapses (n) | First line treatment | Stage |
|---|---|---|---|---|---|---|---|
All patients Median (std dev) | 11:10 M:F | 53 (14) | 63 (90) | 3 (2) | |||
pcALCL* | pcALCL | M | 48 | 43 | 1 | Radiotherapy, CHOP, bortezomib | T3bN0M0 |
pcALCL | pcALCL | M | 33 | 22 | 1 | Radiotherapy | T3bN0M0 |
pcALCL | pcALCL | M | 69 | 92 | 3 | Radiotherapy | T1bN1M0 |
pcALCL | pcALCL | F | 73 | 26 | N/A | N/A | T1aN1M1 |
pcALCL | pcALCL | M | 32 | 117 | 3 | ProMACE CytaBOM | T3bN0M0 |
pcALCL | pcALCL | F | 58 | 4 | 0 | N/A | T1aN0M0 |
pcALCL | pcALCL | M | 46 | 7 | 0 | Radiotherapy | T1bN0M0 |
pcALCL | pcALCL | F | 46 | 64 | 5 | Excision | T2aN0M0 |
pcALCL | pcALCL | M | 83 | 17 | 0 | None | T2aN1M0 |
pcALCL - Median (std dev) | 6:3 M:F | 52 (17) | 24 (37) | 1 (2) | |||
Borderline | pcALCL | F | 53 | 293 | 7 | Excision | T1aN0M0 |
Borderline | Borderline | F | 58 | 110 | 3 | None | T3aN0M0 |
Borderline | Borderline | F | 64 | 63 | N/A | Excision | T3bN0M0 |
Borderline | Borderline | F | 49 | 3 | 0 | Prednisone | T3bN0M0 |
Borderline - Median (std dev) | 0:4 M:F | 56 (6) | 87 (108) | 3 (3) | |||
LyP | LyP-C | F | 34 | 214 | 5 | Topical corticosteroid | |
LyP* | LyP-A | F | 47 | 334 | 4 | Prednisone, cyclophosphamide | |
LyP | LyP-A | M | 57 | 86 | N/A | N/A | |
LyP | LyP-A | F | 29 | 118 | 4 | Phototherapy^ | |
LyP | LyP-A | M | 54 | 16 | 1 | Methotrexate | |
LyP | LyP-A | M | 43 | 87 | 5 | Phototherapy | |
LyP | LyP-A | M | 61 | 11 | N/A | Methotrexate | |
LyP | LyP-A | M | 59 | 40 | 1 | Topical corticosteroid | |
LyP - Median (std dev) | 5:3 M:F | 51 (11) | 87 (103) | 4 (2) |